auranofin


Also found in: Wikipedia.

auranofin

 [aw-ran´o-fin]
a gold-containing compound that is a disease-modifying antirheumatic drug used to treat active rheumatoid arthritis, usually that not adequately controlled by nonsteroidal antiinflammatory drugs, or nondrug therapy such as physical therapy; administered orally.

auranofin

(ô-răn′ə-fĭn)
n.
A gold-containing compound used to treat rheumatoid arthritis.

auranofin

A gold preparation that can be taken by mouth for the treatment of RHEUMATOID ARTHRITIS. A brand name is Ridaura.
References in periodicals archive ?
Concomitant RA medications were permitted at the discretion of the investigator and included: methotrexate, leflunomide, sulfasalazine, antimalarials, auranofin injectable gold preparations, nonsteroidal anti-inflammatory drugs, and/or glucocorticoids at approved doses.[28]
Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.
Klegeris, "A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases," Neural Regeneration Research, vol.
Chun, "Auranofin suppresses plasminogen activator inhibitor-2 expression through annexin A5 induction in human prostate cancer cells," Biomolecules & Therapeutics, vol.
crassiceps TGR was obtained by incubating an enzyme aliquot in the presence of a 4:1 molar excess of the irreversible inhibitor auranofin [14].
A number of new molecules have been identified as inhibitors of IL-1[beta] processing (glyburide, parthenolide, CRID3, auranofin, isoliquiritigenin, [beta]-hydroxybutyrate, and MCC950); however, confirming their clinical utility will require additional time and research [24].
However, auranofin, a gold-containing chemical applied for treatment of rheumatoid arthritis, inhibits thioredoxin reductase, inducing ROS formation and in this way dramatically inhibiting GIST cell growth, and it also induces apoptosis in imatinib-resistant cells [60].
Module Drug Drug Drug class target (2) JAK1 Tofacitinib DMARDs JAK2 Tofacitinib DMARDs (4) IL1B Canakinumab Biotech agents IL6R Tocilizumab Biotech agents LTA Etanercept Biotech agents Etanercept Biotech agents Adalimumab Biotech agents TNF Infliximab Biotech agents Golimumab Biotech agents Certolizumab pegol Biotech agents Chloroquine DMARDs TNFRSF1B Etanercept Biotech agents (5) IL1R1 Anakinra Biotech agents (6) PTK2B Leflunomide DMARDs (7) MAPK3 Sulindac NSAIAs CHUK Sulfasalazine DMARDs (8) IKBKB Sulfasalazine DMARDs Auranofin DMARDs (9) PDPK1 Celecoxib NSAIAs (10) BCL2 Ibuprofen NSAIAs
cDMARDs n (%) Patients with at 11,511 (91.9%) least one treatment Methotrexate 9,508 (75.9%) Hydroxychloro quine 3,527 (28.2%) Leflunomide 3,275 (26.1%) Sulfasalazine 2,340 (18.7%) Sodium aurothiomalate 114 (0.9%) Azathioprine 98 (0.8%) Cyclosporine 89 (0.7%) Auranofin 43 (0.3%) Penicillamine 28 (0.2%) Cyclophosphamide 10 (0.1%) bDMARDs n (%) Patients with at 3,697 (29.5%) least one treatment Etanercept 1,545 (12.3%) Adalimumab 1,329 (10.6%) Tocilizumab 618 (4.9%) Abatacept 481 (3.8%) Golimumab 376 (3.0%) Rituximab 339 (2.7%) Certolizumab pegol 273 (2.2%) Infliximab 68 (0.5%) Anakinra 3 (<1.0%) Table 3: Change in DAS28-ESR scores over a 6-month period.
Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.
Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53.